Pulmonary hypertension in chronic lung disease and hypoxia.
Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, Olsson KM, Peacock AJ, Pepke-Zaba J, Provencher S, Weissmann N, Seeger W.
Eur Respir J. 2019 Jan 24;53(1):1801914. doi: 10.1183/13993003.01914-2018. Print 2019 Jan.
Pathophysiology of Group 3 Pulmonary Hypertension Associated with Lung Diseases and/or Hypoxia.
Nakamura K, Akagi S, Ejiri K, Taya S, Saito Y, Kuroda K, Takaya Y, Toh N, Nakayama R, Katanosaka Y, Yuasa S.
Int J Mol Sci. 2025 Jan 20;26(2):835. doi: 10.3390/ijms26020835.
Pathology and pathobiology of pulmonary hypertension: current insights and future directions.
Guignabert C, Aman J, Bonnet S, Dorfmüller P, Olschewski AJ, Pullamsetti S, Rabinovitch M, Schermuly RT, Humbert M, Stenmark KR.
Eur Respir J. 2024 Oct 31;64(4):2401095. doi: 10.1183/13993003.01095-2024. Print 2024 Oct.
Persistent pulmonary hypertension of the newborn.
Mandell E, Kinsella JP, Abman SH.
Pediatr Pulmonol. 2021 Mar;56(3):661-669. doi: 10.1002/ppul.25073.
ErbB3 Governs Endothelial Dysfunction in Hypoxia-Induced Pulmonary Hypertension.
Bian JS, Chen J, Zhang J, Tan J, Chen Y, Yang X, Li Y, Deng L, Chen R, Nie X.
Circulation. 2024 Nov 5;150(19):1533-1553. doi: 10.1161/CIRCULATIONAHA.123.067005. Epub 2024 Jan 12.
Endothelial FUNDC1 Deficiency Drives Pulmonary Hypertension.
Pei Y, Ren D, Yin Y, Shi J, Ai Q, Hao W, Luo X, Zhang C, Zhao Y, Bai C, Zhu L, Wang Q, Li S, Zhang Y, Lu J, Liu L, Zhou L, Wu Y, Weng Y, Jing Y, Lu C, Cui Y, Zheng H, Li Y, Chen G, Hu G, Chen Q, Liao X.
Circ Res. 2025 Jan 17;136(2):e1-e19. doi: 10.1161/CIRCRESAHA.124.325156. Epub 2024 Dec 10.
Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression.
Born E, Lipskaia L, Breau M, Houssaini A, Beaulieu D, Marcos E, Pierre R, Do Cruzeiro M, Lefevre M, Derumeaux G, Bulavin DV, Delcroix M, Quarck R, Reen V, Gil J, Bernard D, Flaman JM, Adnot S, Abid S.
Circulation. 2023 Feb 21;147(8):650-666. doi: 10.1161/CIRCULATIONAHA.122.058794. Epub 2022 Dec 14.
Targeting VEGF-A/VEGFR2 Y949 Signaling-Mediated Vascular Permeability Alleviates Hypoxic Pulmonary Hypertension.
Zhou W, Liu K, Zeng L, He J, Gao X, Gu X, Chen X, Jing Li J, Wang M, Wu D, Cai Z, Claesson-Welsh L, Ju R, Wang J, Zhang F, Chen Y.
Circulation. 2022 Dec 13;146(24):1855-1881. doi: 10.1161/CIRCULATIONAHA.122.061900. Epub 2022 Nov 17.
Targeting Endothelial ENO1 (Alpha-Enolase) -PI3K-Akt-mTOR Axis Alleviates Hypoxic Pulmonary Hypertension.
Shi Y, Liu J, Zhang R, Zhang M, Cui H, Wang L, Cui Y, Wang W, Sun Y, Wang C.
Hypertension. 2023 May;80(5):1035-1047. doi: 10.1161/HYPERTENSIONAHA.122.19857. Epub 2023 Mar 8.
GLI1+ Cells Contribute to Vascular Remodeling in Pulmonary Hypertension.
Chu X, Kheirollahi V, Lingampally A, Chelladurai P, Valasarajan C, Vazquez-Armendariz AI, Hadzic S, Khadim A, Pak O, Rivetti S, Wilhelm J, Bartkuhn M, Crnkovic S, Moiseenko A, Heiner M, Kraut S, Atefi LS, Koepke J, Valente G, Ruppert C, Braun T, Samakovlis C, Alexopoulos I, Looso M, Chao CM, Herold S, Seeger W, Kwapiszewska G, Huang X, Zhang JS, Pullamsetti SS, Weissmann N, Li X, El Agha E, Bellusci S.
Circ Res. 2024 May 24;134(11):e133-e149. doi: 10.1161/CIRCRESAHA.123.323736. Epub 2024 Apr 19.
